Skip to main content

Master of Public Health

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.

AUTHORS

Oliveira DB , Iwane MK , Prill MM , Weinberg GA , Williams JV , Griffin MR , Szilagyi PG , Edwards KM , Staat MA , Hall CB , Durigon EL , Erdman DD , . Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 4 ; 65(). 26-31
  • NIHMSID: 9815671

ABSTRACT

Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ.

Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ.

Tags: